Nautilus Biotechnology, Inc.

conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today. Jian Yi, Investor Relations.

Thank you. Earlier today, Nautilus released financial results for the quarter ended March 31, 2025. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujil Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowery, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on April 29, 2025. With that, I'll turn the call over to Sujal.

Thanks, Jian, and thank you all for joining us today. Q1 was a productive quarter for Nautilus as we continued to advance our mission of unlocking the full potential of the proteome. We're making solid progress across many fronts as we work to bring uniquely valuable proteomic data to biomedical researchers across both modalities of our platform. Targeted proteoform detection, an area where we're making rapid advancements and we'll discuss extensively this morning. and broad scale discovery. The evolution of our broad scale development activities, as we reported on in detail last call, continues on schedule and in a way that we believe reduces technical risk while yielding the greatest possible platform performance ahead of the planned launch of our broad scale product in late 2026. As you'll hear in more detail from Parag in a few moments, I was really pleased with the recent results of the internal verification and validation, or V&V work, we've done on our tau proteoform assay. The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. As I mentioned previously, a major goal in the first half of 2025 is to provide leading researchers with access to our platform for tau-related proteoform studies. We're confident that 2025 will be the year that researchers begin to apply the platform's capabilities to ask and answer important questions about the role of tau proteoforms in Alzheimer's disease and other neurodegenerative diseases. To that point, we continue to hear enthusiastic expressions of interest from customers and partners in our tau capabilities in particular and targeted proteoform detection more broadly in both public and private contexts. For example, a recent Genome Web article quoted a well-known East Coast researcher speaking about the Nautilus platform as follows. I think this is just the beginning of really understanding what these different tau molecules are. The excitement for us is that with Nautilus, we're seeing this at the single molecule resolution Going down the road, as they add to that collection of antibodies, that increased complexity will tell us even more about how tau is modified and what the consequences of those modifications could be. On a related note, in Q1, we undertook a series of in-depth interviews with more than 30 proteomics researchers across academia, pharma, and nonprofits with the goal of more fully understanding and identifying the defining characteristics of our potential customer segments, and the drivers of adoption across a number of dimensions, demographics, research focus, maturity, objectives, expectations, lab characteristics, financial, and organizational considerations. Through these conversations, we validated that there continues to be significant interest in both the targeted Proteform and broad-scale discovery capabilities of our platform. These researchers were particularly consistent in their belief that their inability to accurately quantify proteoforms in a reproducible manner is a major inhibitor to future biological advancements. Customer after customer spoke of their current frustrations and how the Nautilus platform could be a new way to ensure a more detailed and accurate understanding of protein modifications. They were then able to draw a straight line between that better understanding and advances in targeted therapeutic development. Recent preliminary partnership-related conversations with several large pharma companies, academia, well-known nonprofit research organizations, and governmental entities also indicate significant interest in targeted proteoform analysis for a wide range of use cases, including drug targeting and drug discovery efforts. We look forward to continuing and formalizing those relationships, and we'll keep you apprised as we continue to move down the partnership path. Needless to say, the experimental findings from our internal V&V work, the results of which we hope to submit for publication in the coming months, and the extremely positive feedback coming from external sources, such as those I just mentioned, has created great anticipation about the potential positive impact our targeted proteoform capabilities may have on Alzheimer's disease and other neurodegenerative diseases and beyond. For a more detailed update on this and our other R&D efforts, let me turn the call over to Parag. Parag?